CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $222,000
- in 2 filings, $222K under 10b5-1 plans
Net −$222,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-04-29 | Fenton Mary Kay Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2024-02-22 | Savill Corrine Chief Business Officer | Grant or award | +37,500 | 203,490 | ||
| 2024-02-22 | Savill Corrine Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2024-02-22 | AHMED NADIM President and CEO | Grant or award | +160,000 | 271,550 | ||
| 2024-02-22 | AHMED NADIM President and CEO | Grant or award · Stock Option (Right to Buy) | +320,000 | 320,000 | ||
| 2024-02-22 | Trigilio Jeffrey Chief Financial Officer | Grant or award | +50,000 | 133,919 | ||
| 2024-02-22 | Trigilio Jeffrey Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2024-02-22 | SUMER JACQUELYN L Chief Legal Officer | Grant or award | +50,000 | 94,133 | ||
| 2024-02-22 | SUMER JACQUELYN L Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2024-02-22 | Michaelson Jennifer Chief Scientific Officer | Grant or award | +50,000 | 137,582 | ||
| 2024-02-22 | Michaelson Jennifer Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2024-02-22 | Jones Jeffrey Alan Chief Medical Officer | Grant or award | +62,500 | 118,691 | ||
| 2024-02-22 | Jones Jeffrey Alan Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2024-02-01 | Savill Corrine Chief Business Officer | Option exercise 10b5-1 | +40,000 | $4.30 | $172K | 205,990 |
| 2024-02-01 | Savill Corrine Chief Business Officer | Sale 10b5-1 | −40,000 | $16.18 | $647K | 165,990 |
| 2024-02-01 | Savill Corrine Chief Business Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −40,000 | 70,331 | ||
| 2024-01-29 | Savill Corrine Chief Business Officer | Option exercise 10b5-1 | +40,000 | $4.30 | $172K | 205,990 |
| 2024-01-29 | Savill Corrine Chief Business Officer | Sale 10b5-1 | −40,000 | $14.09 | $564K | 165,990 |
| 2024-01-29 | Savill Corrine Chief Business Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −13,997 | 0 | ||
| 2024-01-29 | Savill Corrine Chief Business Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −26,003 | 110,331 |
Page 7 of 23 · 446 trades